VetDC, a Colorado State University startup company, is dedicated to bringing innovative pet cancer therapeutics to market. In addition to TANOVEA-CA1 for canine lymphoma, VetDC is developing VDC-597, a novel, dual-acting PI3K/mTOR inhibitor, for multiple veterinary cancers, such as hemangiosarcoma and osteosarcoma.

VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology. Data from this publication and several new VetDC-sponsored studies was prominently featured in a State of the Art presentation at the Veterinary Cancer Society (VCS) Annual Conference this past weekend in Portland, Oregon, with nearly 700 veterinary healthcare professionals in attendance.

TANOVEA-CA1 (rabacfosadine for injection) is a novel small molecule drug designed to preferentially target and attack rapidly dividing cancer cells implicated in lymphoma. TANOVEA-CA1 has demonstrated anti-tumor activity in both naïve and relapsed canine lymphoma cases, with a generally well-tolerated safety profile. TANOVEA-CA1 is administered intravenously every three weeks for up to five doses.

TANOVEA-CA1 is commercially available in the US for purchase by licensed veterinarians. TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs.

Learn more from the original post here.